Cargando…

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis

INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Eusebi, Paolo, Giannandrea, David, Biscetti, Leonardo, Abraha, Iosief, Chiasserini, Davide, Orso, Massimiliano, Calabresi, Paolo, Parnetti, Lucilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916700/
https://www.ncbi.nlm.nih.gov/pubmed/27297011
http://dx.doi.org/10.1136/bmjopen-2016-011113
_version_ 1782438866422071296
author Eusebi, Paolo
Giannandrea, David
Biscetti, Leonardo
Abraha, Iosief
Chiasserini, Davide
Orso, Massimiliano
Calabresi, Paolo
Parnetti, Lucilla
author_facet Eusebi, Paolo
Giannandrea, David
Biscetti, Leonardo
Abraha, Iosief
Chiasserini, Davide
Orso, Massimiliano
Calabresi, Paolo
Parnetti, Lucilla
author_sort Eusebi, Paolo
collection PubMed
description INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodies (LBs), which are intracytoplasmic inclusions in substantia nigra neurons. The major component of LBs, α-synuclein (α-syn), has been implicated in the pathogenesis of PD and in other ‘synucleinopathies’ such as multisystem atrophy (MSA) and dementia with LBs (DLBs). Several studies have investigated this presynaptic protein as a potential biomarker of PD. The aim of our meta-analysis is to determine the ability of cerebrospinal fluid (CSF) concentrations of total α-syn, oligomeric α-syn and phosphorylated α-syn to discriminate patients with PD from healthy participants, non-degenerative neurological controls and patients suffering from parkinsonism and or synucleinopathies. METHODS AND ANALYSIS: This systematic review protocol has been developed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocol (PRISMA-P) 2015 statement and was registered on PROSPERO (CRD42016013217). We will search Cochrane Library, Web of Science, MEDLINE (via PubMed) and EMBASE from inception, using appropriate search strategies. Two independent reviewers will screen titles, abstracts and full-text articles, and will complete data abstraction. We will include studies that involved patients with PD, DLB, MSA, progressive supranuclear palsy, corticobasal disease and vascular PD, and in which at least one between total α-syn, oligomeric α-syn and phosphorylated α-syn was measured in CSF. To evaluate the risk of bias and applicability of primary diagnostic accuracy studies, we will use QUADAS-2. ETHICS AND DISSEMINATION: Our study will not include confidential data, and no intervention will be involved, so ethical approval is not required. The results of the study will be reported in international peer-reviewed journals.
format Online
Article
Text
id pubmed-4916700
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49167002016-06-24 Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis Eusebi, Paolo Giannandrea, David Biscetti, Leonardo Abraha, Iosief Chiasserini, Davide Orso, Massimiliano Calabresi, Paolo Parnetti, Lucilla BMJ Open Neurology INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodies (LBs), which are intracytoplasmic inclusions in substantia nigra neurons. The major component of LBs, α-synuclein (α-syn), has been implicated in the pathogenesis of PD and in other ‘synucleinopathies’ such as multisystem atrophy (MSA) and dementia with LBs (DLBs). Several studies have investigated this presynaptic protein as a potential biomarker of PD. The aim of our meta-analysis is to determine the ability of cerebrospinal fluid (CSF) concentrations of total α-syn, oligomeric α-syn and phosphorylated α-syn to discriminate patients with PD from healthy participants, non-degenerative neurological controls and patients suffering from parkinsonism and or synucleinopathies. METHODS AND ANALYSIS: This systematic review protocol has been developed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocol (PRISMA-P) 2015 statement and was registered on PROSPERO (CRD42016013217). We will search Cochrane Library, Web of Science, MEDLINE (via PubMed) and EMBASE from inception, using appropriate search strategies. Two independent reviewers will screen titles, abstracts and full-text articles, and will complete data abstraction. We will include studies that involved patients with PD, DLB, MSA, progressive supranuclear palsy, corticobasal disease and vascular PD, and in which at least one between total α-syn, oligomeric α-syn and phosphorylated α-syn was measured in CSF. To evaluate the risk of bias and applicability of primary diagnostic accuracy studies, we will use QUADAS-2. ETHICS AND DISSEMINATION: Our study will not include confidential data, and no intervention will be involved, so ethical approval is not required. The results of the study will be reported in international peer-reviewed journals. BMJ Publishing Group 2016-06-13 /pmc/articles/PMC4916700/ /pubmed/27297011 http://dx.doi.org/10.1136/bmjopen-2016-011113 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Neurology
Eusebi, Paolo
Giannandrea, David
Biscetti, Leonardo
Abraha, Iosief
Chiasserini, Davide
Orso, Massimiliano
Calabresi, Paolo
Parnetti, Lucilla
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title_full Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title_fullStr Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title_full_unstemmed Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title_short Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
title_sort diagnostic utility of csf α-synuclein species in parkinson's disease: protocol for a systematic review and meta-analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916700/
https://www.ncbi.nlm.nih.gov/pubmed/27297011
http://dx.doi.org/10.1136/bmjopen-2016-011113
work_keys_str_mv AT eusebipaolo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT giannandreadavid diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT biscettileonardo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT abrahaiosief diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT chiasserinidavide diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT orsomassimiliano diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT calabresipaolo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis
AT parnettilucilla diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis